Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1958 1
1970 1
1972 1
1975 1
1977 4
1980 4
1982 1
1985 1
1988 3
1990 2
1991 1
1992 1
1993 2
1994 5
1995 1
2000 2
2001 2
2002 1
2003 1
2004 3
2005 3
2006 11
2007 10
2008 12
2009 14
2010 15
2011 11
2012 13
2013 14
2014 11
2015 15
2016 18
2017 24
2018 11
2019 7
2020 16
2021 25
2022 20
2023 9
2024 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

263 results

Results by year

Filters applied: . Clear all
Page 1
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.
Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, Call TG, Catovsky D, Dearden C, Demeter J, Else M, Forconi F, Gozzetti A, Ho AD, Johnston JB, Jones J, Juliusson G, Kraut E, Kreitman RJ, Larratt L, Lauria F, Lozanski G, Montserrat E, Parikh SA, Park JH, Polliack A, Quest GR, Rai KR, Ravandi F, Robak T, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam C, Tiacci E, Troussard X, Zent CS, Zenz T, Zinzani PL, Falini B. Grever MR, et al. Among authors: call tg. Blood. 2017 Feb 2;129(5):553-560. doi: 10.1182/blood-2016-01-689422. Epub 2016 Nov 30. Blood. 2017. PMID: 27903528 Free PMC article.
AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells.
Sakemura RL, Hefazi M, Cox MJ, Siegler EL, Sinha S, Hansen MJ, Stewart CM, Feigin JM, Manriquez Roman C, Schick KJ, Can I, Tapper EE, Horvei P, Adada MM, Bezerra ED, Kankeu Fonkoua LA, Ruff MW, Forsman CL, Nevala WK, Boysen JC, Tschumper RC, Grand CL, Kuchimanchi KR, Mouritsen L, Foulks JM, Warner SL, Call TG, Parikh SA, Ding W, Kay NE, Kenderian SS. Sakemura RL, et al. Among authors: call tg. Cancer Immunol Res. 2023 Sep 1;11(9):1222-1236. doi: 10.1158/2326-6066.CIR-22-0254. Cancer Immunol Res. 2023. PMID: 37378662 Free PMC article.
Drug Addiction and Histone Code Alterations.
Kim HD, Call T, Magazu S, Ferguson D. Kim HD, et al. Among authors: call t. Adv Exp Med Biol. 2017;978:127-143. doi: 10.1007/978-3-319-53889-1_7. Adv Exp Med Biol. 2017. PMID: 28523544 Review.
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease.
HPS3/TIMI55–REVEAL Collaborative Group; Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, Wiviott SD, Cannon CP, Braunwald E, Sammons E, Landray MJ. HPS3/TIMI55–REVEAL Collaborative Group, et al. N Engl J Med. 2017 Sep 28;377(13):1217-1227. doi: 10.1056/NEJMoa1706444. Epub 2017 Aug 28. N Engl J Med. 2017. PMID: 28847206 Free article. Clinical Trial.
Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia.
Ravandi F, Kreitman RJ, Tiacci E, Andritsos L, Banerji V, Barrientos JC, Bhat SA, Blachly JS, Broccoli A, Call T, Chihara D, Dearden C, Demeter J, Dietrich S, Else M, Epperla N, Falini B, Forconi F, Gladstone DE, Gozzetti A, Iyengar S, Johnston JB, Jorgensen J, Juliusson G, Lauria F, Lozanski G, Parikh SA, Park JH, Polliack A, Quest G, Robak T, Rogers KA, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam CS, Thompson PA, Troussard X, Zent CS, Zenz T, Zinzani PL, Wörmann B, Rai K, Grever M. Ravandi F, et al. Among authors: call t. Blood Cancer J. 2022 Dec 13;12(12):165. doi: 10.1038/s41408-022-00760-z. Blood Cancer J. 2022. PMID: 36509740 Free PMC article. Review.
Hairy cell leukemia and COVID-19 adaptation of treatment guidelines.
Grever M, Andritsos L, Banerji V, Barrientos JC, Bhat S, Blachly JS, Call T, Cross M, Dearden C, Demeter J, Dietrich S, Falini B, Forconi F, Gladstone DE, Gozzetti A, Iyengar S, Johnston JB, Juliusson G, Kraut E, Kreitman RJ, Lauria F, Lozanski G, Parikh SA, Park J, Polliack A, Ravandi F, Robak T, Rogers KA, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam CS, Tiacci E, Troussard X, Zent C, Zenz T, Zinzani PL, Wörmann B. Grever M, et al. Among authors: call t. Leukemia. 2021 Jul;35(7):1864-1872. doi: 10.1038/s41375-021-01257-7. Epub 2021 May 4. Leukemia. 2021. PMID: 33947938 Free PMC article. Review.
Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia.
Hampel PJ, Parikh SA, Call TG, Shah MV, Bennani NN, Al-Kali A, Rabe KG, Wang Y, Muchtar E, Leis JF, Kenderian SS, Koehler AB, Schwager SM, Slager SL, Kay NE, Hanson CA, Van Dyke DL, Shi M, Ding W. Hampel PJ, et al. Among authors: call tg. Blood Cancer J. 2021 Mar 2;11(3):47. doi: 10.1038/s41408-021-00443-1. Blood Cancer J. 2021. PMID: 33654067 Free PMC article. No abstract available.
Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms.
Grever M, Andritsos L, Anghelina M, Arons E, Banerji V, Barrientos J, Bhat SA, Blachly J, Broccoli A, Call T, Dearden C, Dietrich S, Else M, Epperla N, Fagarasanu A, Falini B, Forconi F, Gozzetti A, Hampel P, Hermel DJ, Iyengar S, Johnston JB, Juliusson G, Kreitman RJ, Lauria F, Lozanski G, Oakes CC, Parikh SA, Park J, Quest G, Rai K, Ravandi F, Robak T, Rogers KA, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam CS, Tiacci E, Troussard X, Wörmann B, Zent CS, Zenz T, Zinzani PL. Grever M, et al. Among authors: call t. Leukemia. 2024 Jul;38(7):1642-1644. doi: 10.1038/s41375-024-02280-0. Epub 2024 Jun 8. Leukemia. 2024. PMID: 38851853 Free PMC article. No abstract available.
263 results